News and Press Releases
NICE recommends UCB’s RYSTIGGO▼ (rozanolixizumab) for adults with antibody-positive generalised myasthenia gravis in Final Draft Guidance
Rozanolixizumab, discovered and developed in the UK, has been recommended by NICE as an add on treatment option for eligible adults with antibody-positive generalised myasthenia gravis (gMG) Recommendation represents three...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 29, 2026
U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: April 20, 2026
IBSA UK&I assumes direct commercial responsibility for ialuril in the UK and Ireland
Transition supports continuity of supply and aligns ialuril with IBSA’s expanding UK uro-gynaecology portfolio 9 April 2026 -- Watford, UK -- IBSA UK&I, the UK subsidiary of Swiss pharmaceutical company...
Category: BioManufacturing, Other, Pharmaceutical
Posted: April 9, 2026
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
21 May 2025 -- Surrey, UK -- Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab)...
Category: Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2025
NICE recommends Yselty▼ (linzagolix) for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis
1 May 2025 -- London, UK -- Theramex is pleased to announce that the National Institute for Health and Care Excellence (NICE) has recommended NHS reimbursement of the extended indication...
Category: Other, Pharmaceutical
Posted: May 1, 2025
Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS
Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands
NICE publishes guidance in England & Wales recommending Altuvoct (efanesoctocog alfa) as a treatment option for people with severe haemophilia A aged 2 years and over
2 April 2025 -- Stockholm, Sweden -- Sobi in the UK today announced that the National Institute for Health and Care Excellence (NICE) has issued its Final Guidance in England...
Category: Clinical Trials, Other, Pharmaceutical
Posted: April 2, 2025
CSL Behring and GKV-Spitzenverband Agree on Reimbursement Price for HEMGENIX® – Europe’s First Gene Therapy for Haemophilia B
2 April 2025 -- Marburg, Germany -- CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX. This...
Category: Other, Pharmaceutical
Posted: April 2, 2025
Carbon Minimal pressurised Metered Dose Inhalers (pMDIs) could save up to 619,000 tonnes of emissions each year, representing up to 7%-10% of NHS Net Zero targets
At a national level, seamless transitioning to a range of carbon minimal pMDIs could save between 415,000 and 619,000 tCO₂e annually, reducing carbon emissions to the equivalent financial value of...
Category: Drug Delivery, Manufacturing and Packing
Posted: March 10, 2025
NHS patients receive medicines manufactured by Octapharma using UK-donated plasma for the first time in almost 30 years
The sole manufacturer for the UK’s Plasma for Medicines (PfM) programme is supporting the Department of Health and Social Care, NHS England, and NHS Blood and Transplant to build resilience...
Category: Other, Pharmaceutical
Posted: March 6, 2025
Medicines manufacturing skills project uses Virtual Reality to help NHS reach net zero
Resilience, a UK government initiative, says its use of VR will reduce travel and waste 10 February 2025 – The recently launched government-funded medicines manufacturing skills project, Resilience, has said...
Category: Manufacturing and Packing
Posted: February 11, 2025
Pfizer’s BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with investigator’s choice of...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 25, 2025
AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Risankizumab will be available on the NHS in Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to,...
Category: Clinical Trials, Pharmaceutical
Posted: January 13, 2025
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness of VYNDAQEL (tafamidis) in Patients with Transthyretin Cardiac Amyloidosis
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. 6 August 2024 -- Walton Oaks, UK -- Pfizer Ltd today announced publication...
Category: Drug Discovery, Other, Pharmaceutical
Posted: August 8, 2024
